AMXT 1501 and DFMO Combination Achieve FDA Orphan Drug Designation

OPACC
1 minute ago
1 min read

The FDA has granted orphan drug designation (ODD) to AMXT 1501 in combination with difluoromethylornithine (Iwilfin; DFMO) for the treatment of patients with neuroblastoma.

Comments

AMXT 1501 and DFMO Combination Achieve FDA Orphan Drug Designation

We can’t neglect the mental toll of a childhood cancer diagnosis

New study: Siblings of children with cancer frequently experience serious suffering

Radiation From Medical Scans May Cause Thousands Of Childhood Cancers, Study Says

Survey: Childhood Cancer Survivors Seek More Support from Healthcare Providers, Peers, and Policymakers

Understanding genomes helps identify kids more likely to develop second cancers

Combo Appears Safe, Effective in High-Risk Intraocular Retinoblastoma

Cancer Vaccine Could Prevent Neuroblastoma From Returning After Antibody Treatment

New Approach for Smarter, Safer Cancer Treatment

Abnormal fusion protein drives childhood brain tumor through condensate formation

Recent Posts

AMXT 1501 and DFMO Combination Achieve FDA Orphan Drug Designation

Comments

AMXT 1501 and DFMO Combination Achieve FDA Orphan Drug Designation

We can’t neglect the mental toll of a childhood cancer diagnosis

New study: Siblings of children with cancer frequently experience serious suffering

Radiation From Medical Scans May Cause Thousands Of Childhood Cancers, Study Says

Survey: Childhood Cancer Survivors Seek More Support from Healthcare Providers, Peers, and Policymakers

Understanding genomes helps identify kids more likely to develop second cancers

Combo Appears Safe, Effective in High-Risk Intraocular Retinoblastoma

Cancer Vaccine Could Prevent Neuroblastoma From Returning After Antibody Treatment

New Approach for Smarter, Safer Cancer Treatment

Abnormal fusion protein drives childhood brain tumor through condensate formation

Archive

Search By Tags